

Title (en)  
COMPOSITIONS HAVING IMPROVED STABILITY

Title (de)  
ARZNEIZUSAMMENSETZUNGEN MIT ERHÖHTER STABILITÄT

Title (fr)  
COMPOSITIONS A STABILITE AMELIOREE

Publication  
**EP 1216044 A1 20020626 (EN)**

Application  
**EP 00970493 A 20000926**

Priority  

- US 0026402 W 20000926
- US 15654099 P 19990929
- US 46733399 A 19991220
- US 17928900 P 20000131

Abstract (en)  
[origin: WO0122967A1] The present invention pertains to improved stability of compositions that deliver pharmaceutical active ingredients. These compositions have exceptional stability when used in various product forms including liquid elixirs placed into the mouth and eventually swallowed, or can be delivered via liquid-filled lozenges, metered liquid dosing devices, atomizers and liquid-releasing, edible capsules. Such compositions are particularly useful for treating symptoms associated with respiratory illnesses.

IPC 1-7  
**A61K 31/485; A61K 9/00; A61K 47/02; A61K 47/10; A61K 47/12; A61K 47/18; A61K 47/20; A61K 47/22; A61K 47/00**

IPC 8 full level  
**A61K 9/08** (2006.01); **A61K 9/00** (2006.01); **A61K 9/12** (2006.01); **A61K 9/20** (2006.01); **A61K 9/48** (2006.01); **A61K 31/485** (2006.01); **A61K 45/06** (2006.01); **A61K 47/00** (2006.01); **A61K 47/02** (2006.01); **A61K 47/04** (2006.01); **A61K 47/08** (2006.01); **A61K 47/10** (2006.01); **A61K 47/12** (2006.01); **A61K 47/14** (2006.01); **A61K 47/18** (2006.01); **A61K 47/20** (2006.01); **A61K 47/22** (2006.01); **A61K 47/24** (2006.01); **A61K 47/32** (2006.01); **A61K 47/34** (2006.01); **A61P 11/00** (2006.01); **A61P 11/02** (2006.01); **A61P 11/04** (2006.01); **A61P 11/10** (2006.01); **A61P 11/12** (2006.01); **A61P 11/14** (2006.01); **A61P 23/02** (2006.01); **A61P 25/06** (2006.01); **A61P 29/00** (2006.01); **A61P 31/12** (2006.01); **A61P 31/16** (2006.01); **A61P 37/08** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP)  
**A61K 9/0056** (2013.01); **A61K 9/006** (2013.01); **A61K 9/0095** (2013.01); **A61K 31/485** (2013.01); **A61K 47/02** (2013.01); **A61K 47/10** (2013.01); **A61K 47/12** (2013.01); **A61K 47/183** (2013.01); **A61K 47/20** (2013.01); **A61K 47/22** (2013.01); **A61P 11/00** (2017.12); **A61P 11/02** (2017.12); **A61P 11/04** (2017.12); **A61P 11/10** (2017.12); **A61P 11/12** (2017.12); **A61P 11/14** (2017.12); **A61P 23/02** (2017.12); **A61P 25/06** (2017.12); **A61P 29/00** (2017.12); **A61P 31/12** (2017.12); **A61P 31/16** (2017.12); **A61P 37/08** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)  
See references of WO 0122967A1

Citation (examination)  

- WO 9413280 A1 19940623 - MAYOR PHARMA LAB INC [US], et al
- COUTEL-EGROS A ET AL.: "Combined effects of pH....", INT J PHARM, vol. 84, 1992, pages 117 - 128
- GHANEM A H ET AL.: "The Effects of Ethanol...", JOURNAL OF CONTROLLED RELEASE, vol. 6, 1987, pages 75 - 83
- DE VRIES M E ET AL.: "Developments in Buccal Drug Delivery", CRITICAL REVIEWS IN THEAPEUTIC DRUG CARRIER SYSTEMS, vol. 8, no. 3, 1991, pages 271 - 303

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 0122967 A1 20010405**; AU 770376 B2 20040219; AU 7986500 A 20010430; BR 0014441 A 20020611; CA 2385990 A1 20010405; CN 1211085 C 20050720; CN 1376065 A 20021023; CO 5210868 A1 20021030; CZ 2002947 A3 20020814; EP 1216044 A1 20020626; HU P0202797 A2 20030128; HU P0202797 A3 20040528; JP 2003510279 A 20030318; MX PA02003312 A 20021004; PE 20010627 A1 20010614

DOCDB simple family (application)  
**US 0026402 W 20000926**; AU 7986500 A 20000926; BR 0014441 A 20000926; CA 2385990 A 20000926; CN 00813496 A 20000926; CO 00074286 A 20000929; CZ 2002947 A 20000926; EP 00970493 A 20000926; HU P0202797 A 20000926; JP 2001526179 A 20000926; MX PA02003312 A 20000926; PE 0010342000 A 20000929